Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lebrikizumab (Primary) ; Pirfenidone
  • Indications Idiopathic pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms The RIFF study
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 02 Oct 2020 Results published in the European Respiratory Journal
    • 20 May 2020 Results of post-hoc exploratory analyses evaluating the associations for imaging features with baseline FVCpp and biomarker levels from CAPACITY-006 (NCT00287729) and RIFF (NCT01872689), presented at the 116th International Conference of the American Thoracic Society.
    • 20 May 2020 Results of post-hoc analysis investigating the relationship between body weight and clinical outcomes over 1 year in patients with Idiopathic Pulmonary Fibrosis from ASCEND [NCT01366209], CAPACITY [NCT00287716 and NCT00287729], INSPIRE [NCT00075998], and RIFF [NCT01872689), presented at the 116th International Conference of the American Thoracic Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top